Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond

被引：0
|
作者：
Hofbauer, C. J. [1 ]
Male, C. [2 ]
Brown, D. [3 ]
Santagostino, E. [4 ]
Oldenburg, J. [5 ]
Scheiflinger, F. [1 ]
Reipert, B. M. [1 ]
机构：
[1] Baxter BioSci, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Texas Houston, Houston, TX USA
[4] Univ Milan, Milan, Italy
[5] Univ Clin Bonn, Bonn, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [21] Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
    Male, Christoph
    Andersson, Nadine G.
    Rafowicz, Anne
    Liesner, R. I.
    Kurnik, Karin
    Fischer, Kathelijn
    Platokouki, Helen
    Santagostino, Elena
    Chambost, Herve
    Nolan, Beatrice
    Koeigs, Christoph
    Kenet, Gili
    Ljung, Rolf
    van den Berg, H. Marijke
    HAEMATOLOGICA, 2021, 106 (01) : 123 - 129
  • [22] Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
    Calvez, Thierry
    Chambost, Herve
    Claeyssens-Donadel, Segolene
    d'Oiron, Roseline
    Goulet, Veronique
    Guillet, Benoit
    Heritier, Virginie
    Milien, Vanessa
    Rothschild, Chantal
    Roussel-Robert, Valerie
    Vinciguerra, Christine
    Goudemand, Jenny
    BLOOD, 2014, 124 (23) : 3398 - 3408
  • [23] Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
    Miri, Syna
    Rosendaal, Frits R.
    Kavakli, Kaan
    Eshghi, Peyman
    Moghaddam, Soha Mohammadi
    Scardo, Sara
    Habibpanah, Behnaz
    Elalfy, Mohsen
    Halimeh, Susan
    Nicolo, Gabriella
    Gokcebay, Dilek
    Ozbek, Namik
    Celkan, Tiraje
    Mohammadi, Ahmad
    Karimi, Mehran
    Shahsavani, Amin
    Yilmaz, Baris
    Albayrak, Canan
    Gunes, Burcak
    Kaya, Zuehre
    Ay, Yilmaz
    Akbayram, Sinan
    Sarper, Nazan
    Mannucci, Pier Mannuccio
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [24] Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
    Paul, Helmut
    Berg, Verena
    Gangadharan, Bagirath
    Bowen, Joel
    LeBeau, Petra
    Blatny, Jan
    Male, Christoph
    Radulescu, Vlad C.
    Diaz, Rosa
    Mancuso, Maria Elisa
    Brown, Deborah L.
    Reipert, Birgit M.
    BLOOD ADVANCES, 2023, 7 (09) : 1831 - 1848
  • [25] LATEST RESULTS FROM THE PUP-GCP CLINICAL TRIAL: A LOW INHIBITOR RATE IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH A PLASMA-DERIVED FVIII CONCENTRATE
    Klukowska, Anna
    Jansen, Martina
    Komrska, Vladimir
    Laguna, Pawel
    Vdovin, Vladimir
    Knaub, Sigurd
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E40 - E41
  • [26] Inhibitor development in relation to treatment duration in severe hemophilia A in previously untreated patients: results from the sippet trial
    Peyvandi, F.
    Mannucci, P. M.
    Garagiola, I
    Anzoletti, M. B.
    El-Beshlawy, A.
    El-Alfy, M.
    Madatha, V. R.
    Eshghi, P.
    Varadarajan, R.
    Hanagavadi, S.
    Karimi, M.
    Manglani, M., V
    Ross, C.
    Young, G.
    Seth, T.
    Apte, S.
    Nayak, D.
    Santagostino, E.
    Mancuso, E.
    Gonzalez, A. C. S.
    Owaidah, Tarek M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 321 - 322
  • [27] Source and purity of factor VIII products as risk factors for inhibitor development in previously untreated patients with severe hemophilia A
    Mancuso, M.
    Mannucci, P.
    Rocino, A.
    Garagiola, I.
    Tagliaferri, A.
    Santagostino, E.
    HAEMOPHILIA, 2012, 18 : 87 - 87
  • [28] The type of products (plasmatic vs recombinant) may exert an influence on FVIII inhibitor incidence in previously untreated severe hemophilia a patients (PUPs).
    Goudemand, J
    Rothschild, C
    Demiguel, V
    Lambert, T
    Calvez, T
    BLOOD, 2003, 102 (11) : 798A - 798A
  • [29] Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A
    Mancuso, Maria Elisa
    Mannucci, Pier Mannuccio
    Rocino, Angiola
    Garagiola, Isabella
    Tagliaferri, Annarita
    Santagostino, Elena
    BLOOD, 2011, 118 (21) : 15 - 16
  • [30] Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada
    Fischer, Kathelijn
    Lassila, Riitta
    Peyvandi, Flora
    Gatt, Alexander
    Hollingsworth, Rob
    Lambert, Thierry
    Kaczmarek, Radek
    Bettle, Amanda
    Samji, Nasrin
    Rivard, Georges-etienne
    Carcao, Manuel
    Iorio, Alfonso
    Makris, Mike
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
12345